TABLE 1.
Clinical Characteristics
| ALA | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 74) | No fluorescence (n = 58) | Fluorescence (n = 16) | |||||||||||||||
| Variable | Avg | SD | M | n | n/N | Avg | SD | M | n | n/N | Avg | SD | M | n | n/N | P a | |
| Age | 42.8 | 13.4 | 41.0 | 42.8 | 13.1 | 41.0 | 43.0 | 14.7 | 41.1 | .956 | |||||||
| Gender | male | 42 | 56.8% | 35 | 60.3% | 7 | 43.8% | .236 | |||||||||
| female | 32 | 43.2% | 23 | 39.7% | 9 | 56.3% | |||||||||||
| KPS | 80 | 4 | 5.4% | 3 | 5.2% | 1 | 6.3% | .030 | |||||||||
| 90 | 12 | 16.2% | 6 | 10.3% | 6 | 37.5% | |||||||||||
| 100 | 58 | 78.4% | 49 | 84.5% | 9 | 56.3% | |||||||||||
| Volume | ccm | 11.4 | 20.1 | 6.00 | 13.0 | 22.5 | 6.00 | 5.79 | 3.16 | 6.0 | .207 | ||||||
| Enhancement | no | 56 | 75.7% | 49 | 84.5% | 7 | 43.8% | .001 | |||||||||
| (weak, indistinct) | yes | 18 | 24.3% | 9 | 15.5% | 9 | 56.3% | ||||||||||
| FETmaxb | 2.45 | 1.29 | 2.35 | 2.24 | 1.29 | 2 | 3.21 | 0.952 | 3 | .009 | |||||||
| EoR | >90% | 24 | 32.4% | 21 | 36.2% | 3 | 18.8% | .187 | |||||||||
| <90% | 50 | 67.6% | 37 | 63.8% | 13 | 81.3% | |||||||||||
| Volume | ccm | 11.4 | 20.1 | 6.00 | 13.0 | 22.5 | 6.00 | 5.79 | 3.16 | 6.0 | .207 | ||||||
| Adj. | none | 39 | 52.7% | 32 | 55.2% | 7 | 43.8% | .335 | |||||||||
| Cytotoxic | chemo | 9 | 12.2% | 8 | 13.8% | 1 | 6.3% | ||||||||||
| Therapy | RT | 24 | 32.4% | 16 | 27.6% | 8 | 50.0% | ||||||||||
| missing | 2 | 2.7% | 2 | 3.4% | 0 | 0.0% | |||||||||||
aChi2 for categories and ANOVA for continuous data; avg, average; SD, standard deviation; M, median; EoR, extent of resection; KPS, Karnofsky Performance Score; ccm, cubic centimeters; FETmax, maxium standard uptake ratio; RT, radiotherapy; chemo, chemotherapy; bn = 70 patients; non-fluorescing tumors: 55, fluorescing tumors 15.